Influenza vaccines represent one of the largest segments of the global vaccine market (with the global market size exceeding $8 billion by 2025). However, the protective efficacy of traditional split-virus vaccines has long hovered between 30% and 50% among individuals aged 65 and older and immunocompromised populations. Additionally, these vaccines require annual updates, offer short-term protection, and lack broad-spectrum coverage, presenting significant challenges for public health and industry advancement. From the perspective of R&D project initiation, the application of AS01 (AS01E/AS01B) in next-generation influenza vaccines possesses strong scientific rationale, clinical translation value, and commercial viability.

By comparing the disease characteristics of influenza with those of RSV and herpes zoster (HZ), we can reasonably infer the core value of the “AS01 adjuvant” in addressing influenza viruses: It does not merely “boost immunity,” but systematically addresses the triple challenge of immune aging, high virality, and recurrent infections. By directly replicating the success logic of Shingrix and Arexvy, it achieves a generational leap from “chasing the virus” to “predictive, long-lasting protection.”

1. Comparison of Disease Characteristics: Precisely Pinpointing the Core Value of a “High-End Adjuvant”

Influenza, RSV, and shingles share significant overlap in high-risk populations (the elderly/immunocompromised) and immune evasion mechanisms. However, influenza’s characteristics of “recurrent infection and extreme variability” make it far more challenging to address than the latter two:

• Common Core Challenges: All three primarily affect individuals aged 65 and older, where immune aging leads to sluggish T/B cell responses and rapid memory cell decline. Traditional vaccines are significantly less effective in this population.

• Flu’s Unique Characteristics: Annual new infections + recurrent infections, extreme antigenic drift/shift (requiring annual strain matching), and a protection duration of only 4–6 months, resulting in “annual vaccinations with inconsistent efficacy.”

• Comparison with RSV: Recurrent infections but slower mutation rates (the preF epitope is relatively conserved); the burden of hospitalizations is highly comparable to that of influenza.

• Comparison with Shingles: Primarily caused by reactivation of latent viruses; antigens are highly conserved, eliminating the need for annual updates.

• Rationale for the project: The true value of high-end adjuvants (such as AS01) lies in precisely addressing the combined challenge of “immunosenescence and complex pathogens.” RSV and HZ have already been successfully validated with AS01: even in the face of immunosenescence in the elderly, protection rates can be boosted from 30–40% to over 90%. As the “most challenging” pathogen, if AS01 can address influenza’s unique challenges (high variability and short-lived protection), the scientific necessity and clinical urgency of this project will far exceed those of ordinary adjuvanted vaccines, making it a “high-risk, high-return” strategic initiative.

2. The Logic Behind the Success of Adjuvanted Rsv and Shingles Vaccines: Evidence of Feasibility for Direct Application to Influenza

Real-world data from Shingrix (gE + AS01B) and Arexvy (RSVPreF3 + AS01E) provide the strongest endorsement for influenza vaccine development:

• Shingrix: Protection rates for those aged 70 and older increased from 38% with traditional live-attenuated vaccines to over 91%, maintaining 79.7% efficacy even after 10 years. The core mechanism is that AS01B strongly activates Th1-biased CD4+ T cells, reversing immune aging.

• Arexvy: 82.6% prevention of lower respiratory tract disease (LRTD) in the first season (94.1% for severe cases), with a cumulative rate of 62.9% over three seasons; particularly effective in elderly populations with comorbidities or immunosuppression. AS01E achieves persistent memory and proper Th1 polarization even at low doses, preventing immune drift.

• Rationale for Project Initiation: AS01 has demonstrated its universality in scenarios involving “the same high-risk populations + recurrent/reactivated diseases.” Influenza and RSV are nearly identical in terms of the burden of hospitalization among the elderly, symptoms, and mechanisms of immune aging (multiple studies in 2025 indicate that the severity of RSV in the elderly has approached or exceeded that of influenza). Initiating this project can directly leverage existing Phase III and post-marketing data, significantly reducing technical risks and regulatory review timelines.

3. Specific Potential and Advantages of AS01E for Influenza Vaccines

From a R&D perspective, the application of AS01E in recombinant HA or nanoparticle influenza vaccines can achieve the following revolutionary breakthroughs:

A. Achieving “Cross-Seasonal” Long-Lasting Protection

The short duration of protection offered by current influenza vaccines is the biggest challenge. AS01E strongly induces long-lasting memory B cells and germinal center responses, which is expected to extend the protection period from 6 months to 2–3 years, potentially enabling a “once-every-two-years” vaccination schedule. Project value: Significantly reduces public health costs and the burden of vaccination adherence among the elderly.

B. Induction of Broad-Spectrum Cross-Protection (Against Variants)

Rapid influenza mutation leads to mismatched vaccines. By strongly recruiting dendritic cells, AS01E promotes recognition of conserved epitopes such as the HA stem, similar to the broad-spectrum efficacy of Arexvy against A/B subtypes and Shingrix against VZV. It can maintain high vaccine efficacy (VE) even during mismatched seasons (current standard vaccines for the elderly achieve only 26–40%). Project Value: Shifting from “chasing viruses annually” to “predictive protection,” establishing a differentiated competitive barrier.

C. Overcoming the “Immune Non-Response” in the Elderly

Traditional vaccines are less effective in individuals aged 65 and older. Through the synergistic action of MPL and QS-21, AS01E induces a cytokine storm—including IFN-γ—locally, forcibly activating the sluggish innate immune response. It is projected that protective efficacy could be boosted to over 80% (comparable to Shingrix). Project Value: Directly fills the gap in high-end influenza vaccines for the elderly, aligning with global aging trends.

D. Dose Efficiency and Pandemic Strategic Value

AS01E’s potent adjuvant effect significantly reduces antigen dosage, enabling rapid production scaling during pandemics. Project Value: Holds national strategic significance while supporting “multi-protection in a single shot” through combination with COVID/RSV vaccines.

Overall Superiority Over Existing Influenza Vaccines:

• vs First-generation split-virus vaccines: Achieves a generational upgrade to “dual humoral and cellular immunity.”

• vs Second-generation MF59/high-dose vaccines: Stronger cellular immunity (Th1/CD8), better durability, no chronic irritation from oil-based emulsions, and superior broad-spectrum coverage.

• Additional Benefits: May reduce the risk of dementia (a 2025 study showed that the incidence of dementia in the AS01 vaccine group was significantly lower than in the conventional influenza vaccine group).

4. Project Feasibility

l High technical feasibility: Leveraging established process templates from Shingrix and Arexvy, formulation optimization and GLP toxicology studies can be completed rapidly.

• Clear Regulatory Pathway: Following the model of Arexvy’s indication expansion for the elderly, Phase III trials can adopt a composite endpoint of non-inferiority plus superiority to accelerate approval.

• Significant Commercial Value: The influenza vaccine market far exceeds that of RSV/HZ. If an AS01-adjuvanted influenza vaccine succeeds, it can serve as a foundational adjuvant platform to integrate multiple respiratory antigens, establishing a multivalent, multi-antigen model for respiratory infectious diseases.

• Risks and Mitigation: Reactivity (slightly higher local reactions with AS01E) can be mitigated through dose optimization and formulation process adjustments; during the early project initiation phase, it is recommended to first conduct Phase I/II immunogenicity bridging trials in the elderly population to rapidly validate Proof of Immunogenicity (POI).

• Project Conclusion: Using AS01 for a new-generation adjuvanted influenza vaccine is a prime project with high strategic value, high clinical demand, and low translation risk.

https://en.jicangbio.com/the-potential-and-advantages-of-using-the-as01-adjuvant.html